相关实验视频
Updated: May 30, 2025
11:07
Focal Laser Ablation of Prostate Cancer: An Office Procedure
Published on: March 30, 2021
7.7K
前列腺动脉栓塞在前列腺癌的设置:审查和意见
Nainesh Parikh1, Kosj Yamoah2, Peter Johnstone2
1Department of Diagnostic Imaging and Interventional Radiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Cancer control : journal of the Moffitt Cancer Center
|January 29, 2025
概括
前列腺动脉栓塞 (PAE) 是对良性前列腺增生的一种微创治疗方法. 本综述更新了PAE在前列腺癌的现状和新兴用途,该癌症目前尚未得到充分研究.
科学领域:
- 干预性放射学 干预性放射学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 在瘤学瘤学.
背景情况:
- 前列腺动脉栓塞 (PAE) 是一种与良性前列腺增生 (BPH) 相关的下尿路症状 (LUTS) 的成熟治疗方法.
- 在治疗前列腺癌中PAE的应用仍然被研究不足.
- 越来越需要探索前列腺癌的新疗法.
研究的目的:
- 提供关于被诊断患有前列腺癌的男性PAE当前状态的最新审查.
- 讨论和强调PAE在前列腺癌管理中的新出现的指示和潜在应用.
- 弥合有关PAE在前列腺癌治疗中的作用的知识差距.
主要方法:
- 对研究前列腺癌中PAE的研究进行了全面的文献搜索.
- 对前列腺癌患者的PAE结果,安全性和疗效现有数据的分析.
- 审查新兴的研究和临床试验,探索PAE的新适应症.
主要成果:
- 在精选的前列腺癌病例中,PAE已经显示出希望,尽管证据有限.
- 需要进一步的研究来建立标准化的协议和长期结果.
- 新出现的迹象表明,在BPH治疗之外,PAE可能存在.
结论:
- PAE是一种正在发展的前列腺癌治疗模式,具有潜在的益处.
- 为了充分了解PAE在瘤学中的有效性和安全性,更广泛的研究是至关重要的.
- 对于特定的前列腺癌患者群体,PAE可能提供一种最小侵入性的选择.
相关概念视频
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
131
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
131
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
146
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
146